Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GPX3 suppresses lung adenocarcinoma progression through HSPB1 ubiquitination and Hippo pathway activation

ABSTRACT: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer; however, its prognosis remains poor, and the underlying molecular mechanisms have yet to be fully elucidated. In this study, a prognostic model was constructed based on manganese metabolism-related genes, which effectively stratifies LUAD patients with different prognoses and drug sensitivity. Mendelian randomization analysis identified glutathione peroxidase 3 (GPX3) as a key prognostic gene, which was downregulated in LUAD and significantly correlated with favorable outcomes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE341979 | GEO | 2026/07/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Development and validation of a 5mC-based prognostic model for lung adenocarcinoma survival: a multicentre, retrospective study

Project description:Lung adenocarcinoma (LUAD) exhibits marked prognostic heterogeneity. Existing methylation-based prognostic models lack robustness, accuracy, or external validation, limiting their clinical utility. We develop MethPro-LUAD, a prognostic model based on eight 5-methylcytosine features, using TCGA-LUAD data (training, N=269; testing, N=180), and validate the model across two independent hospital cohorts (Beijing, N=195; Nanjing, N=88) and two external GEO datasets (N=82 and N=155) to ensure its generalizability and effectiveness. MethPro-LUAD stratifies patients into high- and low-risk groups, with high-risk individuals consistently showing significantly shorter overall survival across all cohorts. In addition, the model’s predictive performance remains robust in subgroups defined by age, sex, stage, and EGFR mutation, and in disease-free survival analyses. Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.

2026-03-06 | GSE295570 | GEO

GPX3 suppresses lung adenocarcinoma progression through HSPB1 ubiquitination and Hippo pathway activation

Project description:GPX3 suppresses lung adenocarcinoma progression through HSPB1 ubiquitination and Hippo pathway activation

| PRJNA1504946 | ENA

Expression data from non-small cell lung carcinoma (NSCLC)

Project description:The analytical validation of a 15 gene prognostic signature for early-stage, completely resected, non-small-cell lung carcinoma that distinguishes between patients with good and poor prognoses.

2014-11-06 | GSE63074 | GEO

Glucose deprivation promotes lung adenocarcinoma de-differentiation due to unbalanced EZH2 activity

Project description:Lung cancer is the most frequent cancer-related cause of death, and adenocarcinoma (LUAD) is the most frequent type. Despite the recent success of immunotherapies, survival of lung cancer patients has not significantly improved in the last decades. New therapies are necessary. We have previously identified sodium-glucose transporter 2 (SGLT2) as the major responsible for glucose uptake in LUAD, and we have showed that treatment with SGLT2 inhibitors significantly delays LUAD development and prolongs survival in murine models. However, our data shows that SGLT2 inhibitors also induce de-differentiation of LUAD cells, leading to a more aggressive phenotype and increased resistance to cisplatin. Glucose deprivation causes reduced αKG levels, leading to reduced activity of αKG-dependent histone demethylases and consequent histone hypermethylation. Supplementation of αKG or inhibition of the histone methyltransferase EZH2 reverse this phenotype, suggesting that this de-differentiated phenotype depends on insufficiency of αKG-dependent histone demethylases and unbalanced EZH2 activity. Consistently, double treatment with an SGLT2 inhibitor and an EZH2 inhibitor significantly reduces the tumor burden in a genetically engineered murine model of LUAD. We further characterized the effect of low glucose-induced tumor de-differentiation, identifying stabilization of hypoxia inducible factor 1α (HIF1α) as a major pathway responsible for the acquisition of a more aggressive phenotype following glucose deprivation. Finally, we identified an HIF1α-dependent transcriptional signature with prognostic significance in human LUAD. Our studies further our knowledge of the relationship between glucose metabolism and cell differentiation in cancer, characterizing the epigenetic adaptation of cancer cells to nutrient deprivation and identifying novel targets to prevent the development of resistance to metabolic therapies.

2022-12-31 | E-MTAB-11253 | biostudies-arrayexpress

Integrated Single-Cell Lung Cancer Atlas Revealed Distinct Fibroblast Phenotypes between Adenocarcinoma and Squamous Cell Carcinomas

Project description:The tumor microenvironment (TME) not only influences cancer progression but has also been shown to have a significant impact on patient prognosis. One of the major TME components is cancer-associated fibroblasts (CAFs), of which several subtypes are identified in tumor tissues. Although scRNA-seq technology is a powerful tool to investigate the cellular proportion and composition in tissues, large-scale datasets are required to analyze a small number of cell populations. Here, we constructed an integrated single-cell RNA-seq dataset for non-small cell lung cancer (NSCLC) by compiling publicly-available data and demonstrated differences in TME heterogeneity and cellular composition between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Particularly, we identified significant differences in CAF subtypes between LUAD and LUSC. Inflammatory CAFs (iCAFs) were dominantly found in LUAD, while myofibroblastic CAFs (mCAFs) were more common in LUSC. Co-culture analysis with lung fibroblasts confirmed that LUAD cells induced iCAF phenotype and, in contrast, LUSC promoted myofibroblastic differentiation. Correlation analysis with patient prognosis identified mCAF as a poor prognostic factor in both LUAD and LUSC, but iCAF was found to be a poor prognostic factor only in LUSC, and vice versa in LUAD. This work highlights important considerations on CAF subtype dominance in LUAD and LUSC, which may relate to patient prognosis.

2025-08-29 | GSE298868 | GEO

microRNA Expression data from Lung cancer cell lines

Project description:GPX3 has been reported to be involved in antioxidant, anticancer, and anti-inflammation in various studies. It is also known that expression of GPX3 is low in lung cancer tissues. We performed a microarray using three lung cancer cell lines including A549, H1650, and H1975 lung cancer cell lines. Among these, A549 is highly expressed in GPX3 as compared with H1650 and h1975. Microarrays were used to analyze microRNAs showing other expression between A549 and the other two cell lines.

2019-01-23 | GSE125018 | GEO

USF1 transcriptionally regulated UGT1A3 and promoted lung adenocarcinoma progression by regulating neurotrophin signaling pathway

Project description:Lung cancer remains the leading cause of oncological death. There is an urgent need to discover new molecular targets and to develop new treatments. Our previous study showed that one of the UDP-glucuronosyltransferases (UGTs) family, UGT1A3, is an important prognostic factor for lung adenocarcinoma (LUAD), inhibiting UGT1A3 could significantly improve the efficacy of anti-tumor drugs. In this study, we aimed to explore the upstream transcriptional factor (USF1) of UGT1A3 and its way of playing a role in LUAD.

2023-11-13 | GSE189607 | GEO

RAD21 reshapes H3K4me3 modification to drive lung adenocarcinoma progression by activating ERK1/2 signal [ChIP-seq]

Project description:RAD21, the core unit of the cohesin complex, is involved in the transcriptional regulation of cells. The high-frequency copy number amplification of RAD21 is general in multiple cancer types and positively correlated with high mRNA levels, such as lung adenocarcinoma (LUAD). However, its role in LUAD is unclear. We found that RAD21 is a poor prognostic factor for LUAD patients. Functionally, depletion of RAD21 using shRNAs impairs LUAD cell proliferation and metastatic ability. Transcriptome sequencing reveals that RAD21 loss inactivates epithelial-mesenchymal transition (EMT) and MAPK signaling pathways in LUAD cell lines, which can be rescued by exogenous RAD21. Pharmacologic ERK1/2 inhibition with specific inhibitor ulixertinib exhibits superior repression on the RAD21-driven high metastatic ability. Clinical exploration using specimens from LUAD patients further validates the correlation between RAD21 and the ERK1/2-EMT process. Taken together, our work reveals the regulatory relationship between RAD21-mediated epigenetic regulation and metastasis signaling cascade in LUAD. The favorable therapeutic efficacy of ulixertinib in mouse models with lung metastasis provides a therapeutic rationale for ERK1/2 inhibition in RAD21-high LUAD.

2026-08-01 | GSE294136 | GEO

RAD21 reshapes H3K4me3 modification to drive lung adenocarcinoma progression by activating ERK1/2 signal

2026-08-01 | GSE294135 | GEO

Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling

Project description:Histologic transformation to small cell lung cancer (SCLC) is an increasingly common resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutant lung adenocarcinoma (LUAD) that is underdiagnosed in clinical practice due to the requirement for tissue biopsy. Early and accurate detection of transformed (t)SCLC has important prognostic and therapeutic implications. To address this unmet need, we first comprehensively profiled the epigenomes of metastatic lung tumors finding widespread epigenomic reprogramming during histologic transformation from LUAD to SCLC. We then utilized a novel approach for epigenomic profiling of cell-free DNA, which discriminated patients with EGFR mutant tSCLC from patients with EGFR mutant LUAD with greater than 90% accuracy. This first demonstration of the ability to accurately, and non-invasively, detect small cell transformation in patients with EGFR mutant LUAD through epigenomic cfDNA profiling is a critical step towards a new paradigm of diagnostic and therapeutic precision for patients with advanced lung cancer.

2024-06-20 | GSE269746 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data